Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
GlaxoSmithKline (United States) · Research Triangle Park Foundation · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
551
total citations
- FWCI
- 42.27
- Percentile
- 100%
- References
- 28
Citations per year
Authors
8- HOHéctor OrtegaCorresponding
GlaxoSmithKline (United States), Research Triangle Park Foundation
- SWSteven W. Yancey
Research Triangle Park Foundation, GlaxoSmithKline (United States)
- BMBhabita Mayer
GlaxoSmithKline (United Kingdom)
- NBNecdet B. Gunsoy
GlaxoSmithKline (United Kingdom)
- ONOliver N. Keene
GlaxoSmithKline (United Kingdom)
Topics & keywords
Topics
Keywords
- Mepolizumab
- Medicine
- Eosinophil
- Asthma
- Eosinophilic
- Baseline (sea)
- Internal medicine
- Eosinophilia
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.